Temporal Trends in Thromboembolic Event Hospitalizations in Patients with Atrial Fibrillation in the United States
Vasquez, M. A.; Yang, C. L.; Lambrakos, L.; Velasquez, A.; Goldberger, J. J.; Mitrani, R. D.
Show abstract
BackgroundDirect oral anticoagulants and percutaneous left atrial appendage occlusion (LAAC) devices were approved for use in 2010 and 2015, respectively. It is unknown to what extent, if any, these new stroke preventive therapies have impacted hospitalizations for thromboembolic (TE) events in the United States. MethodsWe used the National Inpatient Sample database to describe trends over time in AF-related hospitalizations for acute ischemic stroke (AIS), transient ischemic attacks (TIA), and systemic embolic events (SEE) between 2010 and 2021. Trends in anticoagulation use (AC) and percutaneous LAAC procedures among hospitalized patients with AF were also analyzed. ResultsA total of 1,692,373 hospitalizations for TE were identified between 2010 and 2021: 798,413 from 2010 to 2015 (mean age 78.9 [standard deviation (SD) 10.7] years; 57.8% female) and 893,960 from 2016 to 2021 (mean age 77.5 [SD 10.9] years; 53.1% female). There was a significant increase in rates of AC use (21.2% of inpatients with AF in 2010 vs 42.4% of inpatients with AF in 2021; Ptrend <0.001) and rates of percutaneous LAAC procedures (0.1/100,000 US adults vs to 17.7/100,000 US adults Ptrend <0.001) among inpatients with AF. Between 2010 to 2021, age-adjusted AIS hospitalizations increased (30.8 hospitalizations /100,000 US adults vs 35.9 hospitalizations/ 100,000 US adults; Ptrend <0.001) and peaked in 2019. Age-adjusted SEE hospitalizations (2.5 hospitalizations /100,000 US adults vs 1.3 hospitalizations/ 100,000 US adults; Ptrend <0.001) and TIA hospitalization(8.5 hospitalizations /100,000 US adults vs 4.3 hospitalizations/ 100,000 US adults; Ptrend <0.001) peaked in 2011 and then decreased. Between 2016 and 2021, age-adjusted AIS hospitalizations plateaued (37.7 hospitalizations/100,000 US adults vs 35.9 hospitalizations/100,000 US adults; APC -4.7%; Ptrend = 0.197). The total of all TE hospitalizations remained stable (41.8 hospitalizations/100,000 US adults vs 41.5 hospitalizations/100,000 US adults; Ptrend 0.689). ConclusionDespite increased anticoagulant and the initial use of percutaneous LAAO, AF-associated TE event hospitalizations in the US have remained stable from 2010 to 2021. Hospitalizations for AF-related TIA and SEE consistently decreased from 2010 to 2021 while AF-related AIS hospitalizations increased from 2010 to 2015 and then plateaued from 2016 to 2021.
Matching journals
The top 5 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Temporal Patterns of Antithrombotic Therapy and Clinical Outcomes After Atrial Fibrillation-Related Stroke 96%
- Prognostic Value of Patient-Reported Outcomes in Predicting Long-term Mortality after Transcatheter Aortic Valve Replacement (TAVR) 94%
- Surgical strategy for atrial functional mitral regurgitation with atrial fibrillation 94%
Similar papers in this journal
- Ticagrelor vs Clopidogrel: the Impact of Platelet Inhibition on Cerebrovascular Microembolic Events during TAVR 95%
- Atrial functional substrates for the prediction of atrial fibrillation recurrence after pulmonary vein isolation 94%
- Sex-Related Outcomes of Transcatheter Aortic Valve Implantation with Self-Expanding or Balloon-Expandable Valves: Insights from the OPERA-TAVI Registry 94%
Similar papers in this journal
- Clinical Outcomes, Management, Healthcare Resource Utilization, and Cost According to the CHA 2 DS 2 -VASc Scores in Asian Patients with Nonvalvular Atrial Fibrillation 98%
- Association of Heart Failure Subtypes and Atrial fibrillation: Data from the Atherosclerosis Risk in Communities (ARIC) Study 95%
- Utility of the CHADS-P 2 A 2 RC score for estimating net adverse clinical events in chronic coronary syndrome patients without atrial fibrillation: insights from the CLIDAS-PCI 94%
Similar papers in this journal
- Differences in coagulation responses to vascular injury between uninterrupted dabigatran and apixaban - a clinical prospective randomized study 96%
- Procedural Volume and Outcomes with Atrial Fibrillation Ablation: A Report from the NCDR AFib Ablation Registry 96%
- Competing Risks in Patients with Primary Prevention Implantable Cardioverters Defibrillators: Global Electrical Heterogeneity and Clinical Outcomes (GEHCO) Study 94%
Similar papers in this journal
- Pacemaker implantation after cardiac surgery: a contemporary, nationwide perspective 94%
- Evaluation of antithrombotic use and COVID-19 outcomes in a nationwide atrial fibrillation cohort 93%
- Lifestyle physical activity intensity and rapid-rate non-sustained ventricular tachycardia in arrhythmogenic cardiomyopathy 91%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.